Cabergoline tablets Side effects of cabergoline at Patient

Be sure to tell your doctor about all medications, vitamins, or herbs you’re taking. To find out how this drug might interact with something else you’re taking, talk to your doctor or pharmacist. Call 911 if your symptoms feel life-threatening or if you think you’re having a medical emergency. Serious side effects and their symptoms can include the following.

• In very rare cases allergic reactions occurred, such as oedema, urticaria, dermatitis and pruritus.
• Doses of cabergoline up to 4.5 mg per week have been used in hyperprolactinaemic patients.
• Since in clinical studies cabergoline has been mainly administered with food and since the tolerability of this class of compounds is improved with food, it is recommended that cabergoline be preferably taken with meals for all the therapeutic indications.
• Median gestational age was 21 weeks, and median participant age was 33.
• It is often helpful to see whether your periods start again when you have stopped breast feeding, and reassess your prolactin levels, before deciding whether or not to resume cabergoline treatment.

Cabergoline should only be used during pregnancy if clearly indicated and after an accurate benefit/risk evaluation. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. • Hypersensitivity to cabergoline, or any of the excipients listed in section 6.1, or any ergot alkaloid. The safety and efficacy of cabergoline has not been investigated in children as Parkinson’s disease does not affect this population. This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution.

Cabergoline may interact with other medications

No information is available on excretion in breast milk in humans; however, lactation is expected to be inhibited/suppressed by cabergoline, in view of its dopamine agonist properties. Mothers should be advised not to breast-feed while being treated with cabergoline. Depending on your prolactinoma, your symptoms and your situation, you may need no treatment at all, or there may be alternatives such as oestrogen or testosterone treatment. If you are not able to tolerate treatment with cabergoline, or if it is not effective zptropin 12 iu in your case, there are similar medications that can be considered, or other treatment options including pituitary surgery. There were maternotoxic effects but no teratogenic effects in mice given cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis. No information is available on the excretion in breast milk in humans; however, mothers should be advised not to breast-feed in case of failed lactation inhibition/suppression by cabergoline.

What other drugs will affect cabergoline?

Of the group of women followed up, 23/29 had ovulatory cycles which continued for greater than 6 months after cabergoline discontinuation. The weekly dose may be given as a single administration or divided into two or more doses per week according to patient tolerability. Division of the weekly dose into multiple administrations is advised when doses higher than 1 mg per week are to be given since the tolerability of doses greater than 1 mg taken as a single weekly dose has been evaluated only in a few patients. Other drugs may affect cabergoline, including prescription and over-the-counter medicines, vitamins, and herbal products. “Given the current lack of evidence-based interventions to prevent breast symptoms in this population, these findings support routine use of cabergoline after second-trimester abortion or pregnancy loss,” Shaw and team concluded in their paper.

Cabergoline is a dopaminergic ergoline derivative endowed with potent and long-lasting dopamine D2 receptor agonist properties. In rats the compound, acting at D2 dopamine receptors on pituitary lactotrophic cells, decreases PRL secretion at oral doses of 3-25 mcg/kg, and in vitro at a concentration of 45 pg/ml. In addition, cabergoline exerts a central dopaminergic effect via D2 receptor stimulation at doses higher than those effective in lowering serum PRL levels. Improvement of motor deficit in animal models of Parkinson’s disease was present at oral daily doses of 1-2.5 mg/kg in rats and at s.c. The recommended therapeutic dosage is 2 mg to 3 mg/day for patients with signs and symptoms of Parkinson’s disease.